Trial · NCT06706401
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
NCT06706401, Phase 3, Recruiting, Centre Leon Berard
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma. Trials, record NCT06706401. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06706401
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
- NCT number
- NCT06706401
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 460 participants, estimated
- Lead sponsor
- Centre Leon Berard
- Conditions
- Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor
- Interventions
- Vesanoid, Standard radiotherapy, Tailored radiotherapy, Cisplatin, Cetuximab
- First posted
- 2024-11-26
- Last updated
- 2026-04-24
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event Free Survival (EFS) | At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years | Event free survival (EFS) is defined as the time from randomisation to apparition of a documented relapse either local or regional or distant according to clinical or radiological assessment, or persistent residual disease including pathologically positive neck node, or death due to any cause. |
| Secondary | Local relapse Free Survival | At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years | Local relapse Free Survival (lrFS, at site of primary tumor) is defined as the delay from randomisation to first local relapse (i.e. primary site) or death. Patients without documented event will be censured at the last adequate visit or tumor evaluation. |
| Secondary | Regional relapse Free survival | At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years | Regional relapse Free survival (rrFS, in the neck) is defined as the delay from randomisation to first regional relapse (i.e. neck) or death. |
| Secondary | Metastasis Free Survival | At 6, 9, 15, 21 and 27 months from randomisation then annually assessed up to 2 years | Metastasis Free Survival (mFS) is the time between randomisation and apparition of first metastasis (date of metastatic diagnosis). Patients without documented event will be censured at the last tumour evaluation. |
| Secondary | Rate of pathologically positive lymph nodes | At 4 months from the completion of (chemo)-radiotherapy | Rate of pathologically positive lymph nodes at neck node dissection performed at 4 months after the completion of (chemo)-radiotherapy for those patients benefiting from a neck node dissection |
| Secondary | Event Free Survival (EFS) | At 4 months from the completion of (chemo)-radiotherapy | Event Free Survival (EFS) considering that pathologically positive neck node within 4 months post-randomisation will not be an event. |
| Secondary | Overall survival | Until up to 2 years follow-up of the last patient enrolled | Overall survival defined as the time from randomisation to death due to any cause. Patient without documented death at the time of analysis will be censored at the date of last known contact. |
| Secondary | Adverse events | From the date of first intake of study drug until 27 months after the randomisation of the last randomised patient | Incidence of any adverse events graded according to NCI-CTCAE V5.0 |
| Secondary | Patient quality of life (EORTC QLQ-C30) | At randomisation, at 6, 9, 15, 21 and 27 months after randomisation and30 days after the last study treatments administration | To assess the impact of the proposed combinations on patient' quality of life in the target population (EORTC QLQ-C30) |
| Secondary | Patient quality of life (EQ5-DL) | At randomisation, at 6, 9, 15, 21 and 27 months after randomisation and30 days after the last study treatments administration | To assess the impact of the proposed combinations on patient' quality of life in the target population (EQ5-DL) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40692081 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06706401
GET https://conductscience.org/api/trials/v1/NCT06706401/registered